{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:45:27Z","timestamp":1782603927598,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Variant Philadelphia chromosome translocations involving chromosomes other than chromosomes 9 and 22 have been reported in 5% to 10% of patients with chronic myeloid leukemia (CML). Here, a case of CML with a t (9, 22, 16) (q34; q11; p13) translocation, which has never been described, is reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 59-year-old female with dry cough, referred to our hospital, exhibited hepatosplenomegaly, high basophil count, and high platelet count at admission without any other known chronic diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with CML with the translocation t (9;22;16) (q34; q11; p13). The patient was treated with imatinib, a first-generation tyrosine kinase inhibitor (TKI), discontinuously, achieving a complete hematological response for 7 years. Since November 8, 2017, the patient had recurrent fever, and her platelet count rose to 1422\u200a\u00d7\u200a10<jats:sup>9<\/jats:sup>\/L. Subsequently, the E279K mutation in the BCR-ABL kinase region was detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>According to a previous report, this mutation confers sensitivity to nilotinib, a second-generation TKI. In the end, the patient received treatment with nilotinib and showed a complete hematological response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The present study reports a rare case of CML with Ph chromosome and a t (9;22;16) (q34; q11; p13) translocation. For such cases about CML with variant Philadelphia chromosome translocations or BCR-ABL kinase region mutation, TKI may still be valuable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000012875","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T23:14:10Z","timestamp":1539818050000},"page":"e12875","source":"Crossref","is-referenced-by-count":3,"title":["Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib"],"prefix":"10.1097","volume":"97","author":[{"given":"Yefei","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann Intern Med"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-61779-074-4_4","article-title":"Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment","volume":"730","author":"Morris","year":"2011","journal-title":"Methods Mol Biol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0165-4608(03)00128-6","article-title":"Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia","volume":"147","author":"Naumann","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3892\/br.2017.967","article-title":"A rare case of three-way complex variant translocation in chronic myeloid leukemia t(6;9;22)(p21;q34;q11): a case report","volume":"7","author":"Asif","year":"2017","journal-title":"Biomed Rep"},{"key":"R6-20230914","first-page":"582016","article-title":"Previously unreported chromosomal aberrations of t(3;3)(q29;q23), t(4;11)(q21;q23), and t(11;18)(q10;q10) in a patient with accelerated phase Ph+ CML","volume":"2014","author":"Aydin","year":"2014","journal-title":"Case Rep Genet"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-4608(03)00204-8","article-title":"Contribution of fluorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocations in chronic myelocytic leukemia","volume":"147","author":"Morel","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3892\/ol.2016.4821","article-title":"A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: a case report","volume":"12","author":"Asif","year":"2016","journal-title":"Oncol Lett"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cancergencyto.2004.08.009","article-title":"A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia","volume":"157","author":"Espinoza","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.3892\/ol.2017.5845","article-title":"An unusual translocation, t(1;11)(q21;q23), in a case of chronic myeloid leukemia with a cryptic Philadelphia chromosome","volume":"13","author":"Gutierrez","year":"2017","journal-title":"Oncol Lett"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.leukres.2018.01.005","article-title":"Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations","volume":"65","author":"Inokuchi","year":"2018","journal-title":"Leuk Res"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000331472","article-title":"Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients","volume":"127","author":"Meggyesi","year":"2012","journal-title":"Acta Haematol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"R16-20230914","article-title":"Mechanisms of resistance to targeted therapies in chronic myeloid leukemia","author":"Lussana","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12185-018-2519-y","article-title":"Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence","volume":"108","author":"Inoue","year":"2018","journal-title":"Int J Hematol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-3148.1991.tb00030.x","article-title":"Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML","volume":"1","author":"McCarthy","year":"1991","journal-title":"Transfus Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-017-0460-4","article-title":"An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia","volume":"17","author":"Repsold","year":"2017","journal-title":"Cancer Cell Int"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood-2002-05-1366","article-title":"High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML","volume":"101","author":"Lange","year":"2003","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201810190-00068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:58:21Z","timestamp":1694714301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201810190-00068"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":23,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012875","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}